肝移植治疗肝门部胆管癌的研究进展

打开文本图片集

DOI： 10.12449/JCH251204

关键词：胆管肿瘤；肝移植；肿瘤辅助疗法；免疫疗法基金项目：国家重点研发计划（2022YFC2304701）；河南省慈善总会肝胆相照基金（GDXZ2019003）

Researchadvances in livertransplantation in treatment of perihilarcholangiocarcinom

WENPeihao，GUOWenzhi

DepartmentofHepatopancreatobiliaryurgery，eFirstAfliatedHospitalofZhengzhouUnversityHennLiverraspltatio Center，Zhengzhou450052，China

Corresponding author：GUO Wenzhi，fccguowz@zzu.edu.cn（ORCID： O000-0002-0821-1318）

Abstract：Periilarcholangiocarcinoma（pCCA）originatesfromthebiliaryepitheliumattheconfluenceoftheleftandright hepaticducts，ndmostpatientsareintheadvanced stageatthetimeofconfirmeddiagnosisduetocomplexanatomy，insidious earlysymptoms，andhighlyaggresivetumorbiologyAlthoughradicalresectionremainsthepreferrdtreatmentmethod，hereis sillalow5-yearsurvivalateaftersurgery.SinceMayoClinicproposedaprotocolcombiningneoadjuvantchemoradiotherapywith strictscreeningcriteria，long-termoutcomesofpCCAhavebeensignificantlyimprovedafterlivertransplantation.Withthe expansionofdonor liversources，thematurationof living-donor livertransplantation techniques，andtheoptimizationof immunosuppresionstrategies，livertransplantationhasgraduallybecomeastandardizedtreatmentregimenforspecificpatients with pCCA.ThisarticlesystematicallreviewsthecurrentstatusoflivertransplantationforthetreatmentofpCCA，thecriteriafor indicatios，thestrategiesforneoadjuvant therapybeforesurgery，postoperativemanagement，andrecurrencepreventionand control，aswellasthedirections forfuturedevelopmentsuchasprecisemolecularsubtyping，combined immunotherapy，andthe optimization of donor organ resources.

Key Words：Bile Duct Neoplasms；Liver Transplantation；Neoadjuvant Therapy；Immunotherapy

Research funding：National KeyResearchandDevelopment Programof China（022YFC2304701）；LiverHealth Foundationof Henan CharityFederation（GDXZ2O19003）

胆管癌（cholangiocarcinoma，CCA）是起源于胆管上皮的恶性肿瘤，可根据解剖位置分为肝内胆管癌、肝门部胆管癌（perihilarcholangiocarcinoma，pCCA）和远端胆管癌。（剩余19407字）